What question did this study set out to answer?

To evaluate the efficacy of tradipitant in preventing vomiting caused by motion sickness in adults.

Tradipitant (Nereus) for Motion Sickness

View Full Paper

Ask AI

Bookmark

Randomized trial shows tradipitant reduces motion-induced vomiting in adults, implying a new treatment option.

To evaluate the efficacy of tradipitant in preventing vomiting caused by motion sickness in adults.
FDA approval process evaluated the effectiveness of tradipitant for motion sickness prevention.
Comparative analysis with existing substance P/NK-1 receptor antagonists was conducted.
Tradipitant is the first new motion sickness medication approved in over 40 years.
Demonstrated significant reduction of vomiting episodes during motion in clinical trials.

A 2026 study studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Randomized trial shows tradipitant reduces motion-induced vomiting in adults, implying a new treatment option.

To evaluate the efficacy of tradipitant in preventing vomiting caused by motion sickness in adults.
FDA approval process evaluated the effectiveness of tradipitant for motion sickness prevention.
Comparative analysis with existing substance P/NK-1 receptor antagonists was conducted.
Tradipitant is the first new motion sickness medication approved in over 40 years.
Demonstrated significant reduction of vomiting episodes during motion in clinical trials.

A 2026 study studied this question.

View Full Paper

Ask AI

Bookmark